RGS Stock Overview
Regeneus Ltd, a clinical stage regenerative medicine company, develops cell-based therapies for the human health markets with a focus on osteoarthritis and other musculoskeletal disorders, neuropathic pain, and dermatology diseases in Australia.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 1/6 |
Dividends | 0/6 |
Regeneus Ltd Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | AU$0.005 |
52 Week High | AU$0.02 |
52 Week Low | AU$0.003 |
Beta | -0.24 |
1 Month Change | -16.67% |
3 Month Change | 66.67% |
1 Year Change | -54.55% |
3 Year Change | -95.65% |
5 Year Change | -95.24% |
Change since IPO | -98.15% |
Recent News & Updates
Shareholder Returns
RGS | AU Biotechs | AU Market | |
---|---|---|---|
7D | 0% | 4.0% | 1.3% |
1Y | -54.5% | 1.2% | 11.5% |
Return vs Industry: RGS underperformed the Australian Biotechs industry which returned 1.4% over the past year.
Return vs Market: RGS underperformed the Australian Market which returned 11.6% over the past year.
Price Volatility
RGS volatility | |
---|---|
RGS Average Weekly Movement | 32.4% |
Biotechs Industry Average Movement | 11.5% |
Market Average Movement | 8.8% |
10% most volatile stocks in AU Market | 17.1% |
10% least volatile stocks in AU Market | 3.2% |
Stable Share Price: RGS's share price has been volatile over the past 3 months.
Volatility Over Time: RGS's weekly volatility has decreased from 41% to 32% over the past year, but is still higher than 75% of Australian stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2007 | n/a | Karolis Rosickas | https://regeneus.com.au |
Regeneus Ltd, a clinical stage regenerative medicine company, develops cell-based therapies for the human health markets with a focus on osteoarthritis and other musculoskeletal disorders, neuropathic pain, and dermatology diseases in Australia. The company’s platform technology includes Progenza, a multi-synergistic therapy, which has completed Phase I clinical trial for the treatment of osteoarthritis; and in pre-clinical stage to treat neuropathic pain. It also develops Sygenus that is in pre-clinical stage for the treatment of skin wound healing.
Regeneus Ltd Fundamentals Summary
RGS fundamental statistics | |
---|---|
Market cap | AU$1.53m |
Earnings (TTM) | -AU$366.01k |
Revenue (TTM) | AU$988.43k |
1.6x
P/S Ratio-4.2x
P/E RatioIs RGS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
RGS income statement (TTM) | |
---|---|
Revenue | AU$988.43k |
Cost of Revenue | AU$0 |
Gross Profit | AU$988.43k |
Other Expenses | AU$1.35m |
Earnings | -AU$366.01k |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -0.0012 |
Gross Margin | 100.00% |
Net Profit Margin | -37.03% |
Debt/Equity Ratio | 0% |
How did RGS perform over the long term?
See historical performance and comparison